Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis.

Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Vaccine (Impact Factor: 3.49). 10/2009; 28(3):623-31. DOI: 10.1016/j.vaccine.2009.10.068
Source: PubMed

ABSTRACT The duration of protection provided by hepatitis B vaccine is still unknown but can be estimated through long-term follow-up studies. Electronic databases and conference databases to December 2008 were searched. Reference lists of articles were screened and the studies authors and manufacturers were contacted for additional unpublished references. Randomized clinical trials and prospective cohort studies addressing the long-term protective effect of hepatitis B vaccine were included in this meta-analysis. We assessed 42 separate cohorts involving overall 11,090 subjects; 34 cohorts involving 9356 subjects were included in the final meta-analysis. Results indicate that the overall cumulative incidence of HBV breakthrough infection 5-20 years post-primary vaccination was 0.007 [95% CI: 0.005 to 0.010] with a variation among studies from 0 to 0.094. Available data do not allow us to exclude an increased risk for infection with time since vaccination. We conclude that the protection provided by three or four doses of monovalent HB vaccine persists for at least two decades in the great majority of immunocompetent individuals. Additional studies are needed for assessing vaccine efficacy for longer periods of time and the need of booster doses in different subgroups of population.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The risk of infection with hepatitis B virus is higher in HIV-infected patients due to shared risk factors. Unfortunately, the efficacy of immunisation against HBV in this group is much worse than in general population. Especially patients with low CD4 cell count and high HIV viral load present with lower rate of response. Therefore the use of double vaccine doses or prolongation of the vaccination schedule is recommended in those whose post-vaccination anti-HBs titers are less than 10 mIU/ml. It is uncertain how to manage the patients with “isolated” anti-HBc, where other serological markers of HBV infection are negative. Some recommend vaccination in these patients as well.It is advisable to measure HBV DNA in patients with “isolated” anti-HBc, as a part of them may present with occult hepatitis B.
    HIV & AIDS Review. 01/2010; 9(4):93-96.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The safety and immunogenicity profiles of currently available recombinant hepatitis B vaccines are excellent. However, it remains a real challenge to induce protective immunity in the target groups that respond poorly or not at all to conventional vaccines. Ideally, a hepatitis B vaccine can be developed that conveys lifelong protection against infection rapidly after the injection of a single dose. Although this goal is far from being reached, important improvements have been made. Novel vaccine adjuvants have been developed that enhance the immunogenicity of recombinant hepatitis B vaccines while maintaining a good safety profile. The different adjuvants and adjuvant systems that are discussed herein have all been thoroughly evaluated in clinical trials and some have reached or are close to reach the market.
    Medical Microbiology and Immunology 12/2014; · 2.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis B (HB) virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, is endemic worldwide. Hepatitis B vaccines became commercially available in the 1980s. The World Health Organization recommended the integration of the HB vaccine into the national immunisation programs in all countries. HBV prevention strategies are classified into three groups: (1) universal vaccination alone; (2) universal vaccination with screening of pregnant women plus HB immune globulin (HBIG) at birth; and (3) selective vaccination with screening of pregnant women plus HBIG at birth. Most low-income countries have adopted universal vaccine programs without screening of pregnant women. However, HB vaccines are not widely used in low-income countries. The Global Alliance for Vaccine and Immunization was launched in 2000, and by 2012, the global coverage of a three-dose HB vaccine had increased to 79%. The next challenges are to further increase the coverage rate, close the gap between recommendations and routine practices, approach high-risk individuals, screen and treat chronically infected individuals, and prevent breakthrough infections. To eradicate HBV infections, strenuous efforts are required to overcome socioeconomic barriers to the HB vaccine; this task is expected to take several decades to complete.
    World journal of gastroenterology : WJG. 07/2014; 20(27):8998-9016.

Full-text (2 Sources)

Available from
May 30, 2014